CN116239694B - Antibodies or antigen binding fragments thereof that specifically bind to PV-1 protein and uses thereof - Google Patents
Antibodies or antigen binding fragments thereof that specifically bind to PV-1 protein and uses thereof Download PDFInfo
- Publication number
- CN116239694B CN116239694B CN202310427097.3A CN202310427097A CN116239694B CN 116239694 B CN116239694 B CN 116239694B CN 202310427097 A CN202310427097 A CN 202310427097A CN 116239694 B CN116239694 B CN 116239694B
- Authority
- CN
- China
- Prior art keywords
- seq
- hlpv
- variable region
- antibody
- chain variable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000012634 fragment Substances 0.000 title claims abstract description 91
- 230000027455 binding Effects 0.000 title claims abstract description 69
- 239000000427 antigen Substances 0.000 title claims abstract description 56
- 102000036639 antigens Human genes 0.000 title claims abstract description 56
- 108091007433 antigens Proteins 0.000 title claims abstract description 56
- 102100022427 Plasmalemma vesicle-associated protein Human genes 0.000 title claims abstract description 36
- 101710193105 Plasmalemma vesicle-associated protein Proteins 0.000 title claims abstract description 35
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract description 59
- 230000000295 complement effect Effects 0.000 claims abstract description 5
- 108020004707 nucleic acids Proteins 0.000 claims description 21
- 102000039446 nucleic acids Human genes 0.000 claims description 21
- 150000007523 nucleic acids Chemical class 0.000 claims description 21
- 239000013598 vector Substances 0.000 claims description 18
- 230000014509 gene expression Effects 0.000 claims description 17
- 239000012620 biological material Substances 0.000 claims description 7
- 244000005700 microbiome Species 0.000 claims description 7
- 238000002360 preparation method Methods 0.000 claims description 4
- 238000012398 clinical drug development Methods 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 description 72
- 210000004027 cell Anatomy 0.000 description 27
- 239000013612 plasmid Substances 0.000 description 24
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 18
- 230000000694 effects Effects 0.000 description 18
- 239000002773 nucleotide Substances 0.000 description 18
- 125000003729 nucleotide group Chemical group 0.000 description 18
- 238000002474 experimental method Methods 0.000 description 17
- 239000013613 expression plasmid Substances 0.000 description 17
- 238000003776 cleavage reaction Methods 0.000 description 16
- 230000007017 scission Effects 0.000 description 16
- 238000000034 method Methods 0.000 description 13
- 238000003259 recombinant expression Methods 0.000 description 13
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 12
- 102000004169 proteins and genes Human genes 0.000 description 11
- 235000018102 proteins Nutrition 0.000 description 10
- 230000009824 affinity maturation Effects 0.000 description 9
- 238000010276 construction Methods 0.000 description 9
- 201000010099 disease Diseases 0.000 description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- 108091026890 Coding region Proteins 0.000 description 8
- 108091028043 Nucleic acid sequence Proteins 0.000 description 8
- 206010064930 age-related macular degeneration Diseases 0.000 description 8
- 230000029087 digestion Effects 0.000 description 8
- 208000002780 macular degeneration Diseases 0.000 description 8
- 108020004705 Codon Proteins 0.000 description 7
- 206010012688 Diabetic retinal oedema Diseases 0.000 description 7
- 239000003153 chemical reaction reagent Substances 0.000 description 7
- 201000011190 diabetic macular edema Diseases 0.000 description 7
- 230000035772 mutation Effects 0.000 description 7
- 108010076504 Protein Sorting Signals Proteins 0.000 description 6
- 101000620348 Homo sapiens Plasmalemma vesicle-associated protein Proteins 0.000 description 5
- 235000001014 amino acid Nutrition 0.000 description 5
- 150000001413 amino acids Chemical class 0.000 description 5
- 230000004888 barrier function Effects 0.000 description 5
- 239000012148 binding buffer Substances 0.000 description 5
- 229910052799 carbon Inorganic materials 0.000 description 5
- 238000010586 diagram Methods 0.000 description 5
- 238000001962 electrophoresis Methods 0.000 description 5
- 239000013604 expression vector Substances 0.000 description 5
- 230000002018 overexpression Effects 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 239000006228 supernatant Substances 0.000 description 5
- 238000000108 ultra-filtration Methods 0.000 description 5
- 239000011534 wash buffer Substances 0.000 description 5
- 210000000170 cell membrane Anatomy 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 230000004927 fusion Effects 0.000 description 4
- 102000054625 human PLVAP Human genes 0.000 description 4
- 238000003018 immunoassay Methods 0.000 description 4
- 108091008146 restriction endonucleases Proteins 0.000 description 4
- 238000012216 screening Methods 0.000 description 4
- 238000001890 transfection Methods 0.000 description 4
- NOIIUHRQUVNIDD-UHFFFAOYSA-N 3-[[oxo(pyridin-4-yl)methyl]hydrazo]-N-(phenylmethyl)propanamide Chemical compound C=1C=CC=CC=1CNC(=O)CCNNC(=O)C1=CC=NC=C1 NOIIUHRQUVNIDD-UHFFFAOYSA-N 0.000 description 3
- 108020004414 DNA Proteins 0.000 description 3
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 3
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 3
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 3
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 3
- 102000003960 Ligases Human genes 0.000 description 3
- 108090000364 Ligases Proteins 0.000 description 3
- 108010003723 Single-Domain Antibodies Proteins 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 239000013599 cloning vector Substances 0.000 description 3
- 230000003511 endothelial effect Effects 0.000 description 3
- 238000001976 enzyme digestion Methods 0.000 description 3
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 238000002823 phage display Methods 0.000 description 3
- 229920001184 polypeptide Polymers 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 208000004644 retinal vein occlusion Diseases 0.000 description 3
- 239000002699 waste material Substances 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- CUKWUWBLQQDQAC-VEQWQPCFSA-N (3s)-3-amino-4-[[(2s)-1-[[(2s)-1-[[(2s)-1-[[(2s,3s)-1-[[(2s)-1-[(2s)-2-[[(1s)-1-carboxyethyl]carbamoyl]pyrrolidin-1-yl]-3-(1h-imidazol-5-yl)-1-oxopropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-methyl-1-ox Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C)C(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C1=CC=C(O)C=C1 CUKWUWBLQQDQAC-VEQWQPCFSA-N 0.000 description 2
- 241000589158 Agrobacterium Species 0.000 description 2
- 241000588986 Alcaligenes Species 0.000 description 2
- 102000005862 Angiotensin II Human genes 0.000 description 2
- 101800000733 Angiotensin-2 Proteins 0.000 description 2
- 241000193830 Bacillus <bacterium> Species 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 206010008190 Cerebrovascular accident Diseases 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 241000588698 Erwinia Species 0.000 description 2
- 241000588722 Escherichia Species 0.000 description 2
- 241000589565 Flavobacterium Species 0.000 description 2
- 241000238631 Hexapoda Species 0.000 description 2
- 208000001344 Macular Edema Diseases 0.000 description 2
- 206010025415 Macular oedema Diseases 0.000 description 2
- 241000589516 Pseudomonas Species 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 208000006011 Stroke Diseases 0.000 description 2
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 2
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 2
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 2
- 101710102828 Vesicle-associated protein Proteins 0.000 description 2
- 239000012491 analyte Substances 0.000 description 2
- 229950006323 angiotensin ii Drugs 0.000 description 2
- 210000004102 animal cell Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 210000004899 c-terminal region Anatomy 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000002490 cerebral effect Effects 0.000 description 2
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 239000012636 effector Substances 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 210000003527 eukaryotic cell Anatomy 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 238000010353 genetic engineering Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000012482 interaction analysis Methods 0.000 description 2
- 230000009878 intermolecular interaction Effects 0.000 description 2
- 230000000302 ischemic effect Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 201000007270 liver cancer Diseases 0.000 description 2
- 208000014018 liver neoplasm Diseases 0.000 description 2
- 201000010230 macular retinal edema Diseases 0.000 description 2
- 238000001742 protein purification Methods 0.000 description 2
- 210000002345 respiratory system Anatomy 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000012096 transfection reagent Substances 0.000 description 2
- 210000005253 yeast cell Anatomy 0.000 description 2
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 241000228212 Aspergillus Species 0.000 description 1
- 108010077805 Bacterial Proteins Proteins 0.000 description 1
- 206010048962 Brain oedema Diseases 0.000 description 1
- 241000702421 Dependoparvovirus Species 0.000 description 1
- 206010012689 Diabetic retinopathy Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 241000701959 Escherichia virus Lambda Species 0.000 description 1
- 241000724791 Filamentous phage Species 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 241000235058 Komagataella pastoris Species 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- 241000713666 Lentivirus Species 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 241000235648 Pichia Species 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- KJTLSVCANCCWHF-UHFFFAOYSA-N Ruthenium Chemical class [Ru] KJTLSVCANCCWHF-UHFFFAOYSA-N 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- 108020005038 Terminator Codon Proteins 0.000 description 1
- 102100023935 Transmembrane glycoprotein NMB Human genes 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 125000000641 acridinyl group Chemical class C1(=CC=CC2=NC3=CC=CC=C3C=C12)* 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 210000004100 adrenal gland Anatomy 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 230000004520 agglutination Effects 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N aspartic acid group Chemical group N[C@@H](CC(=O)O)C(=O)O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- OWMVSZAMULFTJU-UHFFFAOYSA-N bis-tris Chemical compound OCCN(CCO)C(CO)(CO)CO OWMVSZAMULFTJU-UHFFFAOYSA-N 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 230000004378 blood-retinal barrier Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 208000006752 brain edema Diseases 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 238000010382 chemical cross-linking Methods 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 239000012149 elution buffer Substances 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 210000003372 endocrine gland Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 102000034287 fluorescent proteins Human genes 0.000 description 1
- 108091006047 fluorescent proteins Proteins 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 239000000833 heterodimer Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 238000003317 immunochromatography Methods 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 239000003547 immunosorbent Substances 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- HWYHZTIRURJOHG-UHFFFAOYSA-N luminol Chemical compound O=C1NNC(=O)C2=C1C(N)=CC=C2 HWYHZTIRURJOHG-UHFFFAOYSA-N 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000002189 macula lutea Anatomy 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 239000012982 microporous membrane Substances 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 230000001817 pituitary effect Effects 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000003127 radioimmunoassay Methods 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 229910052707 ruthenium Inorganic materials 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000010474 transient expression Effects 0.000 description 1
- 108091007466 transmembrane glycoproteins Proteins 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241000701447 unidentified baculovirus Species 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
- 239000011800 void material Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57438—Specifically defined cancers of liver, pancreas or kidney
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/10—Plasmid DNA
- C12N2800/106—Plasmid DNA for vertebrates
- C12N2800/107—Plasmid DNA for vertebrates for mammalian
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/04—Endocrine or metabolic disorders
- G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/16—Ophthalmology
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/16—Ophthalmology
- G01N2800/164—Retinal disorders, e.g. retinopathy
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2871—Cerebrovascular disorders, e.g. stroke, cerebral infarct, cerebral haemorrhage, transient ischemic event
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
Antibodies or antigen binding fragments thereof that specifically bind to PV-1 protein and uses thereof are disclosed. The antibody or antigen binding fragment thereof comprises a heavy chain variable region and a light chain variable region, the determinant complementary regions of the heavy chain variable region and the light chain variable region each consisting of CDR1, CDR2 and CDR 3; the amino acid sequence of CDR1 of heavy chain variable region is shown in 26-35 positions of SEQ ID NO. 5, etc.; the amino acid sequence of CDR2 of heavy chain variable region is shown in 50-66 positions of SEQ ID NO. 5, etc.; the amino acid sequence of CDR3 of heavy chain variable region is shown in 97-101 positions of SEQ ID NO. 5, etc.; the amino acid sequence of CDR1 of the light chain variable region is shown in positions 24-34 of SEQ ID NO. 15 and the like; the amino acid sequence of CDR2 of the light chain variable region is shown in positions 50-56 of SEQ ID NO. 15 and the like; the amino acid sequence of CDR3 of the light chain variable region is shown in positions 89-97 of SEQ ID NO. 15, etc. The affinity of the antibody or antigen binding fragment thereof is improved by 1-2 orders of magnitude compared with that of the original antibody, and the theory can reduce the dosage and accelerate the clinical drug development of new PV-1 targets.
Description
The application is a divisional application with the application number of 202210501892.8 and the application date of 2022.05.09 and the application and creation name of an antibody or an antigen binding fragment thereof which specifically binds to PV-1 protein and application thereof.
Technical Field
The application belongs to the field of monoclonal antibodies of biotechnology, and particularly relates to an antibody specifically binding to PV-1 protein or an antigen binding fragment thereof and application thereof.
Background
The organism substance exchange is that oxygen absorbed by respiratory system and nutrient substances absorbed by digestive system enter blood first and then enter cells in vivo through tissue fluid; at the same time, waste and carbon dioxide generated by in vivo cell metabolism enter tissue fluid and then enter blood to be transported to urinary system and respiratory system to be discharged outside.
The exchange of substances between blood vessels and tissues is an important component of the exchange of biological substances, mainly through two pathways, namely the vascular endothelial cell void or the micropores (or pits) with the membrane. The plasma membrane vesicle associated protein (Plasmalemma vesicle-associated protein, PLVAP, abbreviated as PV-1) has a molecular weight of about 55-60kD, and is a type II transmembrane glycoprotein, which is the only endothelial vascular microporous membrane or plasma membrane cavity membrane protein known at present. PV-1 is expressed at low or no levels in tissues other than those of the endocrine glands such as pituitary, adrenal gland and lung. The expression of PV-1 is obviously up-regulated when the abnormal states such as tumor, hypoxia, trauma and inflammation are accompanied by pathological changes of angiogenesis.
The presence of numerous vascular-tissue barriers within a living organism is of great importance in maintaining the normal physiological state of the living organism, such as vascular-brain tissue barriers (blood-brain barriers) and vascular-retina barriers (blood-retina barriers). The endothelial vessel wall in the vascular-tissue barrier has no plasma membrane micropores or pits and no PV-1 protein expression, but the vascular-tissue barrier structure is destroyed under pathological conditions such as ischemic cerebral apoplexy, primary or metastatic tumor of brain, diabetic retinopathy and the like, and the endothelial vessel wall has micropores and is accompanied with PV-1 antigen expression.
In conclusion, the PV-1 protein is expected to be a new target for treating diseases such as Age-related macular degeneration (Age-related Macular Degeneration, AMD), diabetic macular edema (Diabetic Macular Edema, DME), macular edema caused by retinal vein occlusion of adult patients and the like. Database search shows that the targets for treating the diseases on the market are Vascular Endothelial Growth Factor (VEGF), angiotensin II (AngII) and the like, and related products of PV-1 targets are temporarily unavailable in enterprise layout.
Disclosure of Invention
It is an object of the present invention to provide antibodies or antigen binding fragments thereof that specifically bind to PV-1 proteins.
The present invention provides an antibody or antigen-binding fragment thereof that specifically binds to a PV-1 protein, the antibody or antigen-binding fragment thereof comprising a heavy chain variable region and a light chain variable region, both consisting of a determinant complementary region and a framework region; the determinant complementary regions of the heavy chain variable region and the light chain variable region are each comprised of CDR1, CDR2 and CDR 3;
the amino acid sequence of CDR1 of the heavy chain variable region is shown as 26-35 positions of SEQ ID NO. 03, SEQ ID NO. 05, SEQ ID NO. 06, SEQ ID NO. 07, SEQ ID NO. 08, SEQ ID NO. 09, SEQ ID NO. 10, SEQ ID NO. 11, SEQ ID NO. 12, SEQ ID NO. 13 or SEQ ID NO. 14;
the amino acid sequence of CDR2 of the heavy chain variable region is shown as 50-66 positions of SEQ ID NO. 03, SEQ ID NO. 05, SEQ ID NO. 06, SEQ ID NO. 07, SEQ ID NO. 08, SEQ ID NO. 09, SEQ ID NO. 10, SEQ ID NO. 11, SEQ ID NO. 12, SEQ ID NO. 13 or SEQ ID NO. 14;
the amino acid sequence of CDR3 of heavy chain variable region is shown in position 97-101 of SEQ ID NO. 03, SEQ ID NO. 05, SEQ ID NO. 06, SEQ ID NO. 07, SEQ ID NO. 08, SEQ ID NO. 09, SEQ ID NO. 10, SEQ ID NO. 11, SEQ ID NO. 12, SEQ ID NO. 13 or SEQ ID NO. 14;
The amino acid sequence of CDR1 of the light chain variable region is shown in SEQ ID NO. 04, SEQ ID NO. 15, SEQ ID NO. 16, SEQ ID NO. 17, SEQ ID NO. 18, SEQ ID NO. 19, SEQ ID NO. 20, SEQ ID NO. 21, SEQ ID NO. 22, SEQ ID NO. 23, SEQ ID NO. 24 or SEQ ID NO. 25 at positions 24-34;
the amino acid sequence of CDR2 of the light chain variable region is shown in positions 50-56 of SEQ ID NO. 04, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24 or 25;
the amino acid sequence of CDR3 of the light chain variable region is shown in positions 89-97 of SEQ ID NO:04, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24 or 25.
The antibody may be a full-length antibody, and the antigen-binding fragment may be a Fab fragment, fv fragment, fab 'fragment, F (ab') 2 fragment, single chain antibody (ScFv), nanobody (single domain antibody), bispecific antibody, or Minimal Recognition Unit (MRU).
Alternatively, according to the antibody or antigen binding fragment thereof described above, the amino acid sequence of the heavy chain variable region is as shown in SEQ ID NO. 03, SEQ ID NO. 05, SEQ ID NO. 06, SEQ ID NO. 07, SEQ ID NO. 08, SEQ ID NO. 09, SEQ ID NO. 10, SEQ ID NO. 11, SEQ ID NO. 12, SEQ ID NO. 13 or SEQ ID NO. 14.
Alternatively, according to the antibody or antigen binding fragment thereof described above, the amino acid sequence of the light chain variable region is as shown in SEQ ID NO. 04, SEQ ID NO. 15, SEQ ID NO. 16, SEQ ID NO. 17, SEQ ID NO. 18, SEQ ID NO. 19, SEQ ID NO. 20, SEQ ID NO. 21, SEQ ID NO. 22, SEQ ID NO. 23, SEQ ID NO. 24 or SEQ ID NO. 25.
Alternatively, the antibody or antigen binding fragment thereof is any one of the following:
an antibody named HLPV-P01, wherein the amino acid sequence of the HLPV-P01 heavy chain variable region is shown as SEQ ID NO. 03, and the amino acid sequence of the light chain variable region is shown as SEQ ID NO. 04;
an antibody named HLPV-P02, wherein the amino acid sequence of the heavy chain variable region of the HLPV-P02 is shown as SEQ ID NO. 05, and the amino acid sequence of the light chain variable region is shown as SEQ ID NO. 15;
an antibody named HLPV-P03, wherein the amino acid sequence of the heavy chain variable region of the antibody HLPV-P03 is shown as SEQ ID NO. 06, and the amino acid sequence of the light chain variable region is shown as SEQ ID NO. 16;
an antibody named HLPV-P04, wherein the amino acid sequence of the HLPV-P04 heavy chain variable region is shown as SEQ ID NO:07, and the amino acid sequence of the light chain variable region is shown as SEQ ID NO: 17;
an antibody named HLPV-P05, wherein the amino acid sequence of the heavy chain variable region of the HLPV-P05 is shown as SEQ ID NO. 08, and the amino acid sequence of the light chain variable region is shown as SEQ ID NO. 18;
An antibody named HLPV-P06, wherein the amino acid sequence of the heavy chain variable region of the HLPV-P06 is shown as SEQ ID NO. 09, and the amino acid sequence of the light chain variable region is shown as SEQ ID NO. 16;
an antibody named HLPV-P07, wherein the amino acid sequence of the heavy chain variable region of the HLPV-P07 is shown as SEQ ID NO. 10, and the amino acid sequence of the light chain variable region is shown as SEQ ID NO. 19;
an antibody named HLPV-P08, wherein the amino acid sequence of the heavy chain variable region of the HLPV-P08 is shown as SEQ ID NO. 11, and the amino acid sequence of the light chain variable region is shown as SEQ ID NO. 20;
an antibody named HLPV-P09, wherein the amino acid sequence of the heavy chain variable region of the HLPV-P09 is shown as SEQ ID NO. 11, and the amino acid sequence of the light chain variable region is shown as SEQ ID NO. 21;
an antibody named HLPV-P10, wherein the amino acid sequence of the heavy chain variable region of the HLPV-P10 is shown as SEQ ID NO. 08, and the amino acid sequence of the light chain variable region is shown as SEQ ID NO. 22;
an antibody named HLPV-P11, wherein the amino acid sequence of the HLPV-P11 heavy chain variable region is shown as SEQ ID NO. 11, and the amino acid sequence of the light chain variable region is shown as SEQ ID NO. 23;
an antibody named HLPV-P12, wherein the amino acid sequence of the HLPV-P12 heavy chain variable region is shown as SEQ ID NO. 12, and the amino acid sequence of the light chain variable region is shown as SEQ ID NO. 24;
An antibody named HLPV-P13, wherein the amino acid sequence of the heavy chain variable region of the HLPV-P13 is shown as SEQ ID NO. 13, and the amino acid sequence of the light chain variable region is shown as SEQ ID NO. 25;
an antibody named HLPV-P14, wherein the amino acid sequence of the heavy chain variable region of the HLPV-P14 is shown as SEQ ID NO. 14, and the amino acid sequence of the light chain variable region is shown as SEQ ID NO. 25.
The above antibody subtype may be a humanized antibody such as IgA, igD, igE, igG, igG2, igG3, igG4, igM-type antibody, etc.; the antibody subtypes mentioned above are, for example, igG1 (N297A) and IgG4 (S228P) which have been depleted of ADCC effects.
Optionally, the antibody or antigen-binding fragment thereof according to the above further comprises a heavy chain constant region and a light chain constant region. The heavy chain constant region is an IgG1 heavy chain constant region, an IgG1 variant heavy chain constant region, an IgG4 heavy chain constant region, or an IgG4 variant heavy chain constant region. The light chain constant region is a light chain constant region of Kappa or a variant thereof. The antibody may specifically be one in which the heavy chain variable region carbon end (C-terminal) is fused to the heavy chain constant region and the light chain variable region carbon end (C-terminal) is fused to the light chain constant region.
The amino acid sequence of the heavy chain constant region of IgG1 was obtained by introducing the N297A mutation (EU numbering) into the heavy chain constant region of IgG1, as shown in UniProtKB database sequence number P01857.1 (2022.02.23, most recently updated). The amino acid sequence of the heavy chain constant region of the IgG4 variant is obtained by introducing an S228P (EU numbering) amino acid mutation into IgG4, such as UniProtKB database sequence number P01861.1 (2022.02.23, most recently updated). The amino acid sequence of the Kappa light chain constant region is shown in UniProtKB database sequence number P01834.2 (2022.02.23, most recently updated).
The nucleotide sequence of the gene encoding the heavy chain constant region may be as shown in SEQ ID No.28 at positions 409-1398 or SEQ ID No.29 at positions 409-1389. The nucleotide sequence of the gene encoding the light chain constant region may be set forth in positions 394-714 of SEQ ID No. 30.
The invention also provides a related biological material of the antibody or the antigen binding fragment thereof, wherein the related biological material is any one of the following:
b1 A nucleic acid molecule encoding the above antibody or antigen binding fragment thereof;
b2 A nucleic acid molecule encoding the heavy and/or light chain of the above antibody or antigen binding fragment thereof;
b3 A nucleic acid molecule encoding the heavy chain variable region and/or the light chain variable region of the above antibody or antigen binding fragment thereof;
b4 An expression cassette comprising any one of the nucleic acid molecules B1) to B3);
b5 A recombinant vector comprising any one of the nucleic acid molecules B1) to B3), or a recombinant vector comprising the expression cassette of B4);
b6 A recombinant microorganism comprising any one of the nucleic acid molecules of B1) to B3), or a recombinant microorganism comprising the expression cassette of B4), or a recombinant microorganism comprising the recombinant vector of B5);
b7 A cell line comprising any of the nucleic acid molecules of B1) to B3), or a cell line comprising the expression cassette of B4), or a cell line comprising the recombinant vector of B5).
Alternatively, according to the related biological materials described above,
b2 A nucleic acid molecule encoding the heavy chain of the antibody or antigen-binding fragment thereof is a nucleic acid molecule having a nucleotide sequence shown as SEQ ID No.28 or SEQ ID No. 29;
b2 A nucleic acid molecule encoding the light chain of the antibody or antigen-binding fragment thereof is a nucleic acid molecule having a nucleotide sequence shown in SEQ ID No. 30;
b3 A nucleic acid molecule encoding the heavy chain variable region of the antibody or antigen binding fragment thereof is a nucleic acid molecule having a nucleotide sequence shown as SEQ ID No.26, wherein CDR1, CDR2 and CDR3 are corresponding 76-105, 148-198, 289-303 bases, respectively;
b3 The nucleic acid molecule encoding the light chain variable region of the antibody or antigen binding fragment thereof is a nucleic acid molecule with a nucleotide sequence shown as SEQ ID No.27, wherein CDR1, CDR2 and CDR3 are corresponding 70-102, 148-168 and 278-291 bases, respectively.
Vectors described herein are well known to those of skill in the art and include, but are not limited to: plasmids, phages (e.g., lambda phage or M13 filamentous phage, etc.), cosmids (i.e., cosmids), viral vectors (e.g., baculovirus vectors, retroviruses (including lentiviruses), adenoviruses, adeno-associated viruses, or herpesviruses (e.g., herpes simplex viruses), etc. In one embodiment of the invention, the vector may specifically be pUC57 or pCGS3. Specifically, the recombinant expression plasmids of pCGS3-HLPV-P00 to P14, pCGS3-HLPV-P03 (S228P), pCGS3-HLPV-P05 (S228P), pCGS3-HLPV-P08 (S228P), pCGS3-HLPV-P09 (S228P), pCGS3-HLPV-P10 (S228P), pCGS3-HLPV-P11 (S228P), pCGS3-HLPV-P14 (S228P), pCGS3-HLPV-P03 (N297A), pCGS3-HLPV-P05 (N297A), pCGS3-HLPV-P08 (N297A), pCGS3-HLPV-P09 (N297A), pCGS3-HLPV-P10 (N297A), pCGS3-HLPV-P11 (N297A) or pCGS3-HLPV-P14 (N297A) prepared in the following examples may be used.
The microorganism described herein may be a yeast, a bacterium or a fungus. Wherein the bacteria may be derived from Escherichia (Escherichia), erwinia (Erwinia), agrobacterium (Agrobacterium), flavobacterium (Flavobacterium), alcaligenes (Alcaligenes), pseudomonas (Pseudomonas), bacillus (Bacillus), etc.; the yeast may be Pichia (P.pastoris).
The cell line (host cell) refers to a cell that can be used to introduce a vector, including but not limited to: eukaryotic cells (e.g., yeast cells, aspergillus), animal cells (e.g., mammalian cells, insect cells), or prokaryotic cells. In one embodiment of the invention, the cell line may specifically be an ExpiCHO-S cell.
The terms "cell" and "cell line" are used interchangeably and all such designations include progeny thereof.
The invention also provides a preparation method of the antibody or the antigen binding fragment thereof, which specifically comprises the following steps: the coding gene of the antibody or the antigen binding fragment thereof is introduced into a host cell through a recombinant expression vector containing the coding gene to obtain a recombinant cell, the supernatant of the recombinant cell is cultured, and the target protein is obtained through affinity chromatography purification.
In the above method, the host cell may be a eukaryotic cell, such as a CHO cell, HEK293 cell, yeast cell or insect cell, etc. In one embodiment of the invention, the animal cell is a CHO cell.
The invention also provides a pharmaceutical composition for improving, preventing or treating a disease associated with PV-1 overexpression, comprising the above-described antibody or antigen-binding fragment thereof, and one or more pharmaceutically acceptable carriers.
The pharmaceutically acceptable carrier may be a diluent, an excipient, a filler, a binder, a wetting agent, a disintegrant, an absorption enhancer, an adsorption carrier, a surfactant, or a lubricant, but is not limited thereto.
The invention also provides a reagent or kit for detecting PV-1, the reagent or kit comprising an antibody or antigen-binding fragment thereof as described in any one of the above.
The invention also provides a conjugate comprising an antibody or antigen-binding fragment thereof of the invention, and a detectable label attached to the antibody or antigen-binding fragment thereof; in particular, the detectable label may be selected from enzymes (e.g. horseradish peroxidase or alkaline phosphatase), chemiluminescent reagents (e.g. acridine esters, luminol and derivatives thereof, or ruthenium derivatives), fluorescent dyes (e.g. fluorescein or fluorescent protein), radionuclides or biotin.
Any of the following uses of the above antibodies or antigen binding fragments thereof, and/or the above biological materials are also within the scope of the present invention:
d1 Use in the manufacture of a medicament for ameliorating, preventing or treating a disease associated with PV-1 overexpression;
d2 Use of a polypeptide for diagnosing or screening a disease associated with PV-1 overexpression;
d3 Use in detecting PV-1;
d4 Use in the preparation of a product for detecting PV-1;
d5 For the preparation of a product for binding to a PV-1 protein.
The PV-1 over-expression related disease may include age-related macular degeneration, diabetic macular edema, macular edema caused by retinal vein occlusion in an adult patient, liver cancer, ischemic cerebral apoplexy, and/or cerebral edema.
The product for detecting the PV-1 comprises a product for detecting antigen-antibody binding by using an enzyme-linked immunosorbent method, an immunofluorescence detection method, a radioimmunoassay, a luminescent immunoassay, a colloidal gold immunochromatography method, an agglutination method, an immunoturbidimetry method and the like.
Further, the product may be a reagent, a kit or a chip.
The medicament, reagent, kit or chip of the invention contains any one of the antibodies or antigen binding fragments thereof or combinations thereof. The kit may be a chemiluminescent immunoassay kit, an enzyme-linked immunoassay kit, a colloidal gold immunoassay kit, or a fluorescent immunoassay kit, but is not limited thereto.
The term "antigen-binding fragment" refers to antigen-binding fragments of antibodies and antibody analogs, which generally include at least a portion of the antigen-binding or variable regions (e.g., one or more CDRs) of the parent antibody (parental antibody). The antigen binding fragments retain at least some of the binding specificity of the parent antibody. Typically, the antigen binding fragment retains at least 10% of the parent binding activity when activity is expressed on a molar basis. In particular, the antigen binding fragment retains at least 20%, 50%, 70%, 80%, 90%, 95% or 100% or more of the binding affinity of the parent antibody to the target.
The term "Fab fragment" is a heterodimer formed by the disulfide bond between the heavy chain Fd and the intact light chain, containing only one antigen binding site. After the coding genes of the heavy chain Fd and the complete light chain are connected and the bacterial protein signal peptide genes are fused, fab antibodies (Fab fragments) can be expressed in the E.coli endocrine, and the complete three-dimensional folding and intra-chain and inter-chain disulfide bonds are realized. The heavy chain Fd refers to about 1/2 of the H chain portion (about 225 amino acid residues, including VH, CH1 and part of the hinge region) of the Fab.
The term "Fv fragment" refers to a functional Fv antibody that can be assembled by separately constructing vectors containing the VH and VL genes, co-transfecting the cells, and separately expressing them; a termination codon may be placed between the VH and VL in the vector to express two small molecule protein fragments, respectively, which are then non-covalently bound to form an Fv antibody (Fv fragment).
The term "Fab ' fragment" contains a portion of one light chain and one heavy chain comprising a VH domain and a CH1 domain and a region between the CH1 and CH2 domains, whereby an inter-chain disulfide bond can be formed between the two heavy chains of two Fab ' fragments to form a F (ab ') 2 molecule.
The term "F (ab') 2 fragment" contains two light chains and two heavy chains comprising portions of the constant region between the CH1 and CH2 domains, thereby forming an interchain disulfide bond between the two heavy chains. Thus, a F (ab ') 2 fragment consists of two Fab' fragments held together by disulfide bonds between the two heavy chains.
The term "single chain antibody (ScFv)" refers to a single polypeptide chain, called a single chain antibody (ScFv), in which the light and heavy chain variable region genes are linked by an appropriate oligonucleotide linker (linker). The polypeptide chain can spontaneously fold into a native conformation, maintaining Fv specificity and affinity.
The term "nanobody (single domain antibody)" means that the antibody heavy chain V region is expressed by genetic engineering methods to obtain an antibody containing only VH fragments. The ability of single domain antibodies to bind to antigen and their stability are essentially identical to those of full antibodies.
The term "bispecific antibody" refers to a bispecific antibody that is produced in large quantities, with high uniformity and purity, by introducing two sets of light and heavy chain genes into myeloma cells, and selecting the appropriate antibody constant regions and Ig types. In addition, bispecific antibodies can also be obtained by chemical cross-linking techniques or hybrid-hybridoma techniques.
The term "Minimal Recognition Unit (MRU)" refers to a single CDR structure comprising only the variable domain, and has a molecular mass of only about 1% of that of an intact antibody, and can bind to the corresponding antigen.
The antibodies of the invention may be prepared by various methods known in the art, for example, by genetic engineering recombinant techniques. For example, DNA molecules encoding the heavy and light chain genes of the antibodies of the invention are obtained by chemical synthesis or PCR amplification. The resulting DNA molecules are inserted into expression vectors, then host cells are transfected, the transfected host cells are cultured under specific conditions, and the antibodies of the invention are expressed. The person skilled in the art can select host cells, expression vectors, methods for introducing the expression vectors into host cells, and methods for isolating and purifying antibodies, which are conventional in the art, as required.
The antigen binding fragments may be produced by recombinant DNA techniques or by enzymatic or chemical cleavage of intact antibodies to produce antigen binding fragments of antibodies, as is well known to those of skill in the art.
According to the embodiment of the invention, a group of affinity matured antibodies which specifically bind with the human plasma membrane vesicle associated protein PV-1 are obtained through two phage screening experiments, the affinity is improved by 1-2 orders of magnitude compared with that of the original antibodies, the dosage of the medicine can be reduced theoretically, the related diseases of PV-1 overexpression such as age-related macular degeneration (AMD) and Diabetic Macular Edema (DME) can be treated, and the clinical medicine development of new PV-1 targets can be accelerated.
Drawings
FIG. 1 shows a nucleic acid electrophoresis identification diagram constructed by a sequence IgG1 full-antibody assembly expression plasmid; the upper diagram is an IgG1 full-resistance assembled expression plasmid light chain construction nucleic acid electrophoresis identification diagram, hindIII and XhoI double digestion are adopted, and vector fragments 9535bp and light chain 723bp are obtained theoretically after digestion, wherein lane A is pCGS3-HLPV-P00L, lane B is pCGS3-HLPV-P01L, C is pCGS3-HLPV-P02L, D is pCGS3-HLPV-P03/06L and E is pCGS3-HLPV-P04L, F is pCGS3-HLPV-P05L, G is pCGS3-HLPV-P07L, H is pCGS3-HLPV-P08L, I is pCGS3-HLPV-P09L, J is pCGS3-HLPV-P10L, K is pCGS3-HLPV-P11L, L is pCGS3-HLPV-P12L, and M is pCGS3-HLPV-P13/14L; the lower diagram is an acid electrophoresis identification diagram of the heavy chain construction of the IgG1 full-antibody assembled expression plasmid, bstBI and PacI are adopted for double digestion, and a carrier fragment 10200bp and a light chain 1409bp are theoretically obtained after digestion, wherein lane numbers sequentially correspond to antibody labels, namely lane 00 is pCGS3-HLPV-P00, lane 01 is pCGS3-HLPV-P00, lane 02 is pCGS3-HLPV-P02 …, and lane 14 is pCGS3-HLPV-P14 expression plasmid.
FIG. 2 shows an SDS-PAGE protein electrophoresis of the assembled whole anti-protein of the sequence IgG 1; SDS-PAGE identification (non-reduced to non-reduced SDS-PAGE, reduced to reduced SDS-PAGE) of the assembled whole anti-protein of wild-type IgG1, wherein the lane numbers correspond to the antibody markers in sequence, i.e.lane 00 is HLPV-P00, lane 01 is HLPV-P01, lane 02-HLPV-P02 …, lane 14 is HLPV-P14 antibody.
FIG. 3 shows construction of nucleic acid electrophoresis identification images by removing ADCC effect full-antibody assembled expression plasmids; the construction only changes the heavy chain base sequence, bstBI and PacI are adopted for double enzyme digestion, the carrier fragment 10200bp and the light chain 1409bp are theoretically obtained after enzyme digestion in lanes 1 to 7, and the carrier fragment 10200bp and the light chain 1400bp are theoretically obtained after enzyme digestion in lanes 8 to 14. Wherein 1 is pCGS3-HLPV-P03 (N297A), 2 is pCGS3-HLPV-P05 (N297A), 3 is pCGS3-HLPV-P08 (N297A), 4 is pCGS3-HLPV-P09 (N297A), 5 is pCGS3-HLPV-P10 (N297A), 6 is pCGS3-HLPV-P11 (N297A), 7 is pCGS3-HLPV-P14 (N297A), 8 is pCGS3-HLPV-P03 (S228P), 9 is pCGS3-HLPV-P05 (S228P), 10 is pCGS3-HLPV-P08 (S228P), 11 is pCGS3-HLPV-P09 (S228P), 12 is pCGS3-HLPV-P10 (S228P), 13 is pCGS3-HLPV-P11 (S228P), and 14 is pCGS3-HLPV-P14 (S228P) recombinant plasmid expression.
FIG. 4 shows an electrophoresis pattern of assembled full-antibody purified SDS-PAGE proteins with ADCC effect removed; the upper panel shows AN IgG1 (N297) type antibody against ADCC effect, and the lower panel shows AN IgG4 (S228P) type antibody against ADCC effect on SDS-PAGE, wherein AN represents purified waste liquid non-reducing SDS-PAGE, BN represents purified protein non-reducing SDS-PAGE, AR represents purified waste liquid reducing SDS-PAGE, and BR represents purified protein reducing SDS-PAGE. Wherein the lane numbers correspond to the antibody markers in order, i.e., lane 03 is HLPV-P03, lane 05 is HLPV-P05, lane 08 is HLPV-P08, lane 09 is HLPV-P09, lane 10 is HLPV-P10, lane 11 is HLPV-P11, and lane 14 is an HLPV-P14 antibody.
Detailed Description
The following detailed description of the invention is provided in connection with the accompanying drawings that are presented to illustrate the invention and not to limit the scope thereof. The examples provided below are intended as guidelines for further modifications by one of ordinary skill in the art and are not to be construed as limiting the invention in any way.
The experimental methods in the following examples, unless otherwise specified, are conventional methods, and are carried out according to techniques or conditions described in the literature in the field or according to the product specifications. Materials, reagents and the like used in the examples described below are commercially available unless otherwise specified.
The main reagents and their manufacturer information in the following examples are as follows:
ExpiCHO-S TM cells: thermo company;
ExpiCHO TM expression Medium: thermo company;
ExpiFectamine TM CHO Transfection Kit: thermo company;
pCGS3 expression vector: merck company;
recombinant human PLVAP/PV-1 protein: abcam company;
protein a pre-loaded chromatographic column: bioengineering (Shanghai) stock Co.Ltd;
Centrifugal Filters millipore Co;
Centrifugal Filters 0.5ml 10Kmillipore Co;
PBS ph7.4 (1×): thermo company;
Sure PAGE TM Bis-Tris,10×8,4-12%,12wells: nanjing Jinsri Biotechnology Co.
The key instruments and their manufacturer information in the following examples are as follows:
gel imaging system: protein Simple company;
eStain TM l1 protein staining instrument: nanjing Jinsri biotechnology Co., ltd;
biacore T200 intermolecular interaction analysis System: GE company.
Example 1 affinity maturation assay
This example demonstrates affinity maturation screening by phage display based on the original antibody (which was designated HLPV-P00, heavy chain variable region as shown in SEQ ID NO:01, light chain variable region as shown in SEQ ID NO: 02). Phage display mutation adopts four combination modes to carry out single-point or double-point saturation mutation, and a mutation library is designed. The theoretical library size was calculated as CDR1 (number of amino acids). Times.20 (20 possibilities per site). Times.CDR 2 (number of amino acids). Times.020. Times.CDR 3 (number of amino acids). Times.20. Taking the stock capacity of number 01 as an example, the stock capacity is 9×20×11×20×9×20=3.96×10 6 (Table 1).
TABLE 1 reservoir capacity statistics for antibody affinity maturation experiments
The first phage selection experiment failed and the antibody affinity increased by less than an order of magnitude. The first round of phage selection experiments assembled 11 full-length antibodies, wherein the affinity of 5 antibodies was increased by more than 2 times, the affinity of the antibody with the highest affinity was increased by 4.8 times, the antibody with the highest affinity was named HLPV-P01, the heavy chain variable region was shown as SEQ ID NO:03, and the light chain variable region was shown as SEQ ID NO: 04.
The second phage selection experiment was again conducted through the designed antibody library shown in Table 1 based on the optimal antibody HLPV-P01 obtained in the first experiment, and affinity maturation was obtained with the antibody names HLPV-P02 to 14 in order, and the sequence of the variable region of the encoded antibody was shown in Table 2.
Table 2: affinity maturation screening antibody sequence statistics
Antibodies to | Heavy chain variable region | Light chain variable region | Remarks |
HLPV-P00 | SEQ ID NO:01 | SEQ ID NO:02 | Original antibody |
HLPV-P01 | SEQ ID NO:03 | SEQ ID NO:04 | Intermediate antibodies |
HLPV-P02 | SEQ ID NO:05 | SEQ ID NO:15 | |
HLPV-P03 | SEQ ID NO:06 | SEQ ID NO:16 | |
HLPV-P04 | SEQ ID NO:07 | SEQ ID NO:17 | |
HLPV-P05 | SEQ ID NO:08 | SEQ ID NO:18 | |
HLPV-P06 | SEQ ID NO:09 | SEQ ID NO:16 | |
HLPV-P07 | SEQ ID NO:10 | SEQ ID NO:19 | |
HLPV-P08 | SEQ ID NO:11 | SEQ ID NO:20 | |
HLPV-P09 | SEQ ID NO:11 | SEQ ID NO:21 | |
HLPV-P10 | SEQ ID NO:08 | SEQ ID NO:22 | |
HLPV-P11 | SEQ ID NO:11 | SEQ ID NO:23 | |
HLPV-P12 | SEQ ID NO:12 | SEQ ID NO:24 | |
HLPV-P13 | SEQ ID NO:13 | SEQ ID NO:25 | |
HLPV-P14 | SEQ ID NO:14 | SEQ ID NO:25 |
Example 2 assembled full antibody molecular validation affinity experiments
1 recombinant expression plasmid construction experiments
The sequences of the IgG1-Fc and kappa chain constant regions (heavy chain variable region carbon-terminal IgG1-Fc and light chain variable region carbon-terminal kappa constant region fusion) were fused according to Table 2, respectively, of example 1, codon optimized and commissioned for biosynthesis, and after ligation of the heavy chain gene sequence to the restriction endonuclease SmaI single cleavage site of the pUC57 cloning vector, the light chain gene sequence was ligated between the cleavage sites of restriction endonucleases SmaI and HindIII of the pUC57 cloning vector, corresponding to the synthetic plasmid names as shown in Table 3.
Table 3: full antibody expression combined heavy and light chain plasmid statistical table
Wherein pUC57-00-L, pUC57-01-L, pUC57-02-L, pUC57-03/06-L, pUC57-04-L, pUC57-05-L, pUC57-07-L, pUC57-08-L, pUC57-09-L, pUC57-10-L, pUC57-11-L, pUC57-12-L and pUC57-13/14-L are light chain plasmids containing complete light chain genes obtained by ligating the 3' -end of the light chain variable region genes (the genes encoding light chains shown as SEQ ID NO:02, SEQ ID NO:04, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:24 and SEQ ID NO: 25) with human Kappa constant region genes, respectively. Wherein the nucleotide sequence of the human Kappa constant region (Kappa constant region) light chain gene is shown at positions 394-714 of SEQ ID No.30, and the human Kappa constant region (Kappa constant region) light chain gene expresses an amino acid sequence as shown in UniProtKB database sequence number P01834.2 (2022.02.23, recently updated).
Wherein pUC57-00-H, pUC57-01-H, pUC57-02-H, pUC57-03-H, pUC57-04-H, pUC57-05/10-H, pUC57-06-H, pUC57-07-H, pUC57-08/09/11-H, pUC57-12-H, pUC57-13-H and pUC57-14-H are heavy chain plasmids containing complete heavy chain genes which are fusion genes obtained by ligating the heavy chain variable region genes (coding genes of SEQ ID NO:01, SEQ ID NO:03, SEQ ID NO:05, SEQ ID NO:06, SEQ ID NO:07, SEQ ID NO:08, SEQ ID NO:09, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13 and SEQ ID NO: 14) with human IgG1 constant region heavy chain genes (IgG 1-Fc), respectively. The nucleotide sequence of the heavy chain gene of the human IgG1 constant region is shown in the 409-1398 th position of SEQ ID No.28, and the expression amino acid sequence of the heavy chain gene of the human IgG1 constant region is shown as UniProtKB database serial number P01857.1 (2022.02.23 is updated recently).
The construction scheme of the recombinant expression plasmid is that a light chain is firstly constructed, after the light chain is constructed, a heavy chain is constructed according to different combination modes of a table 3 on the basis, and finally a double expression frame recombinant expression plasmid is formed, and 13 light chain intermediate plasmids and 15 total antibody molecules are constructed in total, and the specific steps are as follows:
The first step is to construct a full anti-molecular light chain, and the operation steps are as follows: the pCGS3 (Merck) vector, pUC57-00-L, pUC57-01-L, pUC57-02-L, pUC57-03/06-L, pUC57-04-L, pUC57-05-L, pUC57-07-L, pUC57-08-L, pUC57-09-L, pUC57-10-L, pUC57-11-L, pUC57-12-L and pUC57-13/14-L light chain plasmids were digested with HindIII (NEB) and XhoI (NEB) to obtain 9535bp vector fragment and 13 723bp light chain fragment. The plasmid was extracted by T4 ligase (TAKARA) ligation, transformation, plating, and double digestion with HindIII and XhoI were performed to identify the digested fragments as expected. The plasmids with correct sequencing were named pCGS3-HLPV-P00L, pCGS3-HLPV-P01L, pCGS3-HLPV-P02L, pCGS3-HLPV-P03/06L, pCGS3-HLPV-P04L, pCGS3-HLPV-P05L, pCGS3-HLPV-P07L, pCGS3-HLPV-P08L, pCGS3-HLPV-P09L, pCGS3-HLPV-P10L, pCGS3-HLPV-P11L, pCGS3-HLPV-P12L, pCGS3-HLPV-P13/14L, respectively (FIG. 1). In the figure, lanes A-M are the results of electrophoresis of intermediate plasmid digestion products of pCGS3-HLPV-P00L, pCGS3-HLPV-P01L, pCGS3-HLPV-P02L, pCGS3-HLPV-P03/06L, pCGS3-HLPV-P04L, pCGS3-HLPV-P05L, pCGS3-HLPV-P07L, pCGS3-HLPV-P08L, pCGS3-HLPV-P09L, pCGS3-HLPV-P10L, pCGS3-HLPV-P11L, pCGS3-HLPV-P12L, and pCGS3-HLPV-P13/14L in this order.
The second step is to construct the full antibody heavy chain and the full antibody according to the different combination modes of the table 3: the 13 intermediate plasmids constructed above and pUC57-00-H, pUC57-01-H, pUC57-02-H, pUC57-03-H, pUC57-04-H, pUC57-05/10-H, pUC57-06-H, pUC57-07-H, pUC57-08/09/11-H, pUC57-12-H, pUC57-13-H and pUC57-14-H heavy chain plasmids were digested with BstBI (NEB) and PacI to obtain 13 10200bp vector fragments and 12 1409bp heavy chain fragments, which were ligated with T4 ligase (TAKARA), transformed, plated, extracted to identify the plasmid, bstBI and PacI by double digestion, and the digested fragments were identical to those expected (FIG. 1, lower). The plasmids sequenced correctly were designated pCGS3-HLPV-P00 to P14, respectively. Lanes 01-14 are shown as the result of electrophoresis of the digestion products of pCGS 3-HLPV-P00-P14, respectively.
Each recombinant expression plasmid of the pCGS3-HLPV-P00 to P14 contains a 1409bp heavy chain gene fragment and a 723bp light chain gene fragment, and the nucleotide sequences of the heavy chain gene fragment and the light chain gene fragment are different only in the nucleotide sequences encoding the heavy chain variable region and the light chain variable region, and the other nucleotide sequences are the same. The amino acid sequences of the corresponding heavy chain variable region and light chain variable region are shown in table 3. Wherein the coding sequence of the heavy chain variable region of the affinity matured sequences HLPV-P02 to P14 of the invention is shown in SEQ ID No.26 (Table 4), the coding sequence of the light chain variable region is shown in SEQ ID No.27 (Table 5), wherein R is A or G, Y is C or T, M is A or C, K is G or T, S is G or C, W is A or T, H is A or T or C, B is G or T or C, V is G or A or C, D is G or A or T, and N is A or T or G or C.
Table 4 degenerate base statistics of SEQ ID No.26 sequence
Table 5 degenerate base statistics of SEQ ID No.27 sequence
The heavy chain gene fragment is shown as SEQ ID NO. 28, bstBI cleavage site at positions 1-6, kozak sequence at positions 7-15, signal peptide gene at positions 16-72, heavy chain gene sequence at positions 73-1398, stop codon at positions 1399-1401, pacI cleavage site at positions 1402-1409, wherein nucleotide sequence at positions 73-408 is coding sequence of heavy chain variable region, and constant region sequence at positions 409-1398.
The light chain gene fragment is shown as SEQ ID NO. 30, hindIII cleavage site is at 1-6 th site, kozak sequence is at 7-15 th site, signal peptide is at 16-72 th site, light chain gene sequence is at 73-714 th site, stop codon is at 715-717 th site, xhoI cleavage site is at 718-723 th site, wherein nucleotide is at 73-393 th site is the coding sequence of light chain variable region, and constant region sequence is at 394-714 th site.
2 transient expression experiment of recombinant expression plasmid
The volume of original plasmid required to transfect 50mL of cells was calculated as the amount of plasmid transfected at 0.8 μg per mL of cell culture and the original concentration of plasmid. 15 recombinant expression plasmids and transfection reagent Expiefectamine TM CHO Transfection Kit (Thermo company) complexes were slowly added dropwise to the cell culture medium ExpiCHO containing ExpiCHO-S cells (Thermo company) TM Expression Medium (Thermo company) to express 15 antibody molecules, shaking the cell culture with the addition of the medium to disperse the DNA and transfection reagent complex uniformly. The feed and enhancer were added at maximum titer 18 to 22h post transfection while the culture conditions were reduced to 32℃at 37℃with CO 2 The concentration is reduced from 8% to 5%; the feed was again added on day 5 post-transfection. When the activity rate is reduced to 65% -75%, stopping culturing to obtain the culture. The resulting cultures were designated CHO-S/pCGS3-HLPV-00 to 14 in sequence for 15 cultures.
3 Assembly Total anti protein purification experiment
Centrifuging the culture at 6000g for 30min, collecting supernatant, and ultrafiltering with ultrafiltration tube Centrifugal Filters Ultrafiltration concentration (Millipore Co.), supernatant and binding/washing buffer (kit components of the biological Protein A pre-packed column) in a volume ratio of 1:1, standing for 20min for full incubation to obtain ultrafiltration concentrated supernatant and a binding/washing buffer solution mixed solution. Five column volumes of binding/washing buffer equilibrate the column (kit components of the biological Protein a pre-packed chromatography column), ultrafiltration concentrate supernatant and binding/washing buffer mix are added to the column and gravity flow is relied on to pass through the pre-packed column. The column was washed with 10-15 column volumes of binding/washing buffer and the flow-through was collected. This procedure was repeated using a new collection tube until the absorbance of the flow-through solution was 280nm near baseline; eluting the recombinant protein on the column with 5-10 column volumes of elution buffer, centrifugal Filters 0.5.5 ml 10K +. >Ultrafiltration concentrate (Millipore Co.) was replaced to PBS (pH 7.4) buffer. Purified monoclonal antibodies were identified using reducing SDS-PAGE and the detection showed that the monoclonal antibody bands were as expected (FIG. 2). Total anti-sample HLPV-P00 to P14 antibodies were from CHO-S/HLPV-00 to 14 cultures, respectively.
4 full anti-molecular affinity assay
The binding affinity of 15 antibodies obtained by affinity maturation of HLPV-P00 to P14 with PV-1 protein is detected by adopting a surface plasma resonance technology. The conjugate recombinant human PLVAP/PV-1 protein (Abcam company) is coupled to a Series S Sensor Chip CM chip (GE company), an antibody obtained by affinity maturation of the analyte flows through the surface of the chip (the temperature is 25 ℃, the flow speed is 30 mu l/min, the binding time is 120s and the dissociation time is 180 s) by a Biacore T200 intermolecular interaction analysis system (GE company), and the conjugate has binding activity with the analyte, so that the refractive index of the surface of a gold film is changed, and finally the SPR angle is changed. By detecting SPR angle changes, biacore T200 Evaluation Software program software outputs raw data and performs a 1:1 binding pattern for kinetic fitting analysis, affinity constants of affinity matured antibodies to PV-1 protein are shown in Table 6.
Table 6 affinity statistics table for affinity maturation total anti-molecular affinity
Antibodies to | Antibody type | Affinity constant | Multiple times | Remarks |
HLPV-P00 | IgG1-Fc | 3.002×10 -8 | 1.00 | Original antibody |
HLPV-P01 | IgG1-Fc | 4.107×10 -9 | 7.31 | Intermediate antibodies |
HLPV-P02 | IgG1-Fc | 2.477×10 -9 | 6.29 | |
HLPV-P03 | IgG1-Fc | 2.239×10 -9 | 13.41 | |
HLPV-P04 | IgG1-Fc | 2.141×10 -9 | 14.02 | |
HLPV-P05 | IgG1-Fc | 1.163×10 -9 | 25.81 | |
HLPV-P06 | IgG1-Fc | 3.353×10 -9 | 8.95 | |
HLPV-P07 | IgG1-Fc | 2.636×10 -9 | 11.39 | |
HLPV-P08 | IgG1-Fc | 7.823×10 -10 | 38.37 | |
HLPV-P09 | IgG1-Fc | 8.149×10 -10 | 36.84 | |
HLPV-P10 | IgG1-Fc | 1.284×10 -9 | 23.38 | |
HLPV-P11 | IgG1-Fc | 7.414×10 -10 | 40.49 | |
HLPV-P12 | IgG1-Fc | 7.317×10 -9 | 4.10 | |
HLPV-P13 | IgG1-Fc | 3.230×10 -9 | 9.29 | |
HLPV-P14 | IgG1-Fc | 3.499×10 -9 | 8.58 |
As can be seen from table 6, two phage display experiments and full anti-molecular affinity experiments demonstrated that 14 affinity matured antibody molecules were obtained in total, with significantly improved affinity compared to the original antibody, with a fold increase of 40.49 times for the highest antibody HLPV-P11 (table 6).
Example 3 affinity studies of antibodies to remove ADCC Effect subtype
1 recombinant expression plasmid construction experiments
The target PV-1 was used clinically without ADCC effect of the antibody, so seven affinity matured antibodies were selected, and recombinant expression plasmids of two subtype antibodies, igG1 (N297A) and IgG4 (S228P), were constructed to attenuate ADCC effect (Table 7) to verify the effect of different ADCC effect subtype-removing antibodies on affinity.
TABLE 7 statistical tables required for removal of ADCC Effect subtype antibody constructions
The IgG1 (N297A) plasmid and the IgG4 (S228P) plasmid were obtained after ligation of the heavy chain gene sequence to the restriction endonuclease SmaI single cleavage site of the pUC57 cloning vector.
Wherein pUC57-03-H (N297A), pUC57-05/10-H (N297A), pUC57-08/09/11-H (N297A), pUC57-14-H (N297A) contains the complete heavy chain gene which is a fusion gene obtained by ligating the 3' -end of the heavy chain variable region gene (encoding genes of SEQ ID NO:06, SEQ ID NO:08, SEQ ID NO:11 and SEQ ID NO: 14) with the human IgG1 (N297A) gene, respectively. Wherein the nucleotide sequence of the IgG1 (N297A) gene is shown in SEQ ID NO. 28, the IgG1 (N297A) gene differs from the human IgG1 constant region only in that the aspartic acid at position 297 is mutated to alanine.
Wherein pUC57-03-H (S228P), pUC57-05/10-H (S228P), pUC57-08/09/11-H (S228P) and pUC57-14-H (S228P) contain complete heavy chain genes which are fusion genes obtained by ligating the 3' -end of the heavy chain variable region genes (encoding genes of SEQ ID NO:06, SEQ ID NO:08, SEQ ID NO:11 and SEQ ID NO: 14) with human IgG4 (S228P) genes, respectively. The nucleotide sequence of the IgG4 (S228P) gene is shown in the 409-1389 th position of SEQ ID No.29, the IgG4 (S228P) gene expresses IgG4 with an amino acid sequence such as that of UniProtKB database with the sequence number P01861.1 (2022.02.23 updated recently) and introduces an IgG4 (S228P) constant region shown by the amino acid mutation of S228P (EU numbering), namely the IgG4 (S228P) gene expresses IgG4 (S228P) which is different from the human IgG4 constant region only by the mutation of serine at the 228 th position to proline.
Plasmids were constructed as in table 7: the 7 intermediate plasmids in Table 7, pUC57-03-H (N297A), pUC57-05/10-H (N297A), pUC57-08/09/11-H (N297A), pUC57-14-H (N297A), pUC57-03-H (S228P), pUC57-05/10-H (S228P), pUC57-08/09/11-H (S228P) and pUC57-14-H (S228P) were digested with the above-described construction, and the 10200bp vector fragment and the 1409bp IgG1 (N297A) or 1400bp IgG4 (S228P) heavy chain fragment were obtained, and the digested fragments were ligated with T4 ligase (TAKARA), transformed, coated, extracted plasmids, bstBI and PacI were digested with the same restriction enzyme as expected (FIG. 3). The plasmids were designated pCGS3-HLPV-P03 (N297A), pCGS3-HLPV-P05 (N297A), pCGS3-HLPV-P08 (N297A), pCGS3-HLPV-P09 (N297A), pCGS3-HLPV-P10 (N297A), pCGS3-HLPV-P11 (N297A), pCGS3-HLPV-P14 (N297A), pCGS3-HLPV-P03 (S228P), pCGS3-HLPV-P05 (S228P), pCGS3-HLPV-P08 (S228P), pCGS3-HLPV-P09 (S228P), pCGS3-HLPV-P10 (S228P), pCGS3-HLPV-P11 (S228P), pCGS3-HLPV-P14 (S228P).
The recombinant expression plasmids of pCGS3-HLPV-P03 (N297A), pCGS3-HLPV-P05 (N297A), pCGS3-HLPV-P08 (N297A), pCGS3-HLPV-P09 (N297A), pCGS3-HLPV-P10 (N297A), pCGS3-HLPV-P11 (N297A) and pCGS3-HLPV-P14 (N297A) each contain 1409bp IgG1 (N297A) heavy chain fragment and 723bp light chain gene fragment, and the nucleotide sequences of the IgG1 (N297A) heavy chain fragment and light chain gene fragment are different from each other except for the nucleotide sequences encoding the heavy chain variable region and the light chain variable region, and the other nucleotide sequences are the same. The heavy chain fragment of IgG1 (N297A) is shown as SEQ ID NO. 28, bstBI cleavage site at positions 1-6, kozak sequence at positions 7-15, signal peptide gene at positions 16-72, heavy chain gene sequence at positions 73-1398, stop codon at positions 1399-1401, pacI cleavage site at positions 1402-1409, wherein nucleotide sequence at positions 73-408 is coding sequence of heavy chain variable region, and constant region sequence at positions 409-1398. The light chain gene fragment is shown as SEQ ID NO. 30, hindIII cleavage site is at the 1 st to 6 th positions, kozak sequence is at the 7 th to 15 th positions, signal peptide is at the 16 th to 72 th positions, light chain gene sequence is at the 73 rd to 714 th positions, stop codon is at the 715 th to 717 th positions, xhoI cleavage site is at the 718 th to 723 th positions, wherein the 73 rd to 393 th nucleotides are the coding sequence of the light chain variable region, and the 394 th to 714 th nucleotides are the constant region sequence.
pCGS3-HLPV-P03(S228P),pCGS3-HLPV-P05(S228P),pCGS3-HLPV-P08
(S228P), pCGS3-HLPV-P09 (S228P), pCGS3-HLPV-P10 (S228P), pCGS3-HLPV-P11 (S228P) and pCGS3-HLPV-P14 (S228P) the 7 recombinant expression plasmids for the subtype antibody deleted for ADCC effect IgG4 (SP 28P) each contain 1400bp of IgG4 (S228P) heavy chain fragment and 723bp of light chain gene fragment, and the nucleotide sequences of the IgG4 (S228P) heavy chain fragment and 723bp of light chain gene fragment are identical except for the nucleotide sequences encoding the heavy chain variable region and the light chain variable region. The heavy chain fragment of IgG4 (S228P) is shown as SEQ ID NO. 29, bstBI cleavage site at positions 1-6, kozak sequence at positions 7-15, signal peptide gene at positions 16-72, heavy chain gene sequence at positions 73-1389, stop codon at positions 1390-1392, pacI cleavage site at positions 1393-1400, wherein nucleotide sequence at positions 73-408 is coding sequence of heavy chain variable region, and constant region sequence at positions 409-1389. The light chain gene fragment is shown as SEQ ID NO. 30, hindIII cleavage site is at the 1 st to 6 th positions, kozak sequence is at the 7 th to 15 th positions, signal peptide is at the 16 th to 72 th positions, light chain gene sequence is at the 73 rd to 714 th positions, stop codon is at the 715 th to 717 th positions, xhoI cleavage site is at the 718 th to 723 th positions, wherein the 73 rd to 393 th nucleotides are the coding sequence of the light chain variable region, and the 394 th to 714 th nucleotides are the constant region sequence.
2 ADCC Effect subtype removal antibody affinity detection
Cultures were obtained by expression of recombinant expression plasmids depleted of ADCC-effector IgG1 (N297A) and IgG4 (SP 28P) subtypes as described in example 2, purified cultures were purified according to the antibody protein purification described in example 2 and purified monoclonal antibodies were identified by SDS-PAGE of the purified cultures, and the detection results showed that the monoclonal antibody bands were expected (FIG. 4), indicating that the aforementioned cultures contained antibodies HLPV-P03, HLPV-P05, HLPV-P08, HLPV-P09, HLPV-P10, HLPV-P11 and HLPV-P14 of the antibody subtype IgG1 (N297A) and antibodies HLPV-P03, HLPV-P05, HLPV-P08, HLPV-P09, HLPV-P10, HLPV-P11 and HLPV-P14 of the antibody subtype IgG4 (S228P), respectively.
The antibodies prepared as described above and HLPV-P00 prepared in example 2 were tested according to the affinity assay method in example 2 for the removal of the affinity constants of ADCC effector subtype antibodies to the PV-1 protein, and the experimental results are shown in Table 8.
TABLE 8 statistical table of ADCC Effect subtype antibody affinities
Table 8 shows that the affinity of antibodies with both IgG1 (N297A) and IgG4 (S228P) removed ADCC effect was increased by 1-2 orders of magnitude over that of the original antibody (HLPV-P00), and the affinity maturation experiment was expected to be applicable to the next drug development experiment.
In summary, the application obtains 14 affinity matured antibody sequences HLPV-P00 to 14 with an affinity enhancement of 1-2 orders of magnitude through two phage selection experiments. Furthermore, the PV-1 target antibody does not need antibody-dependent cell-mediated cytotoxicity (ADCC), and the affinity is still improved by 1-2 orders of magnitude by adopting two antibody subtypes of IgG1 (N297A) and IgG4 (S228P) to remove the ADCC effect. The affinity matured antibody of the application is expected to reduce the dosage of administration and is used for treating diseases such as age-related macular degeneration (AMD), diabetic Macular Edema (DME), and diseases such as macula lutea, liver cancer and the like caused by retinal vein occlusion of adult patients.
The present application is described in detail above. It will be apparent to those skilled in the art that the present application can be practiced in a wide range of equivalent parameters, concentrations, and conditions without departing from the spirit and scope of the application and without undue experimentation. While the application has been described with respect to specific embodiments, it will be appreciated that the application may be further modified. In general, this application is intended to cover any variations, uses, or adaptations of the application following, in general, the principles of the application and including such departures from the present disclosure as come within known or customary practice within the art to which the application pertains. The application of some of the basic features may be done in accordance with the scope of the claims that follow.
Claims (7)
1. An antibody or antigen-binding fragment thereof that specifically binds to a PV-1 protein, characterized in that: the antibody or antigen binding fragment thereof comprises a heavy chain variable region and a light chain variable region, both consisting of a determinant complementary region and a framework region; the determinant complementary regions of the heavy chain variable region and the light chain variable region are each comprised of CDR1, CDR2 and CDR 3;
the amino acid sequence of CDR1 of the heavy chain variable region is shown in positions 26-35 of SEQ ID NO. 6;
the amino acid sequence of CDR2 of the heavy chain variable region is shown in positions 50-66 of SEQ ID NO. 6;
the amino acid sequence of CDR3 of the heavy chain variable region is shown in positions 97-101 of SEQ ID NO. 6;
the amino acid sequence of CDR1 of the light chain variable region is shown in positions 24-34 of SEQ ID NO. 16;
the amino acid sequence of CDR2 of the light chain variable region is shown in positions 50-56 of SEQ ID NO. 16;
the amino acid sequence of CDR3 of the light chain variable region is shown in positions 89-97 of SEQ ID NO. 16.
2. The antibody or antigen-binding fragment thereof of claim 1, wherein: the amino acid sequence of the heavy chain variable region is shown as SEQ ID NO. 6.
3. The antibody or antigen-binding fragment thereof of claim 1, wherein: the amino acid sequence of the light chain variable region is shown as SEQ ID NO. 16.
4. The antibody or antigen-binding fragment thereof of claim 1, wherein: the antibody or antigen binding fragment thereof is HLPV-P03, the amino acid sequence of the heavy chain variable region of the HLPV-P03 is shown as SEQ ID NO. 6, and the amino acid sequence of the light chain variable region is shown as SEQ ID NO. 16.
5. The antibody or antigen-binding fragment thereof of any one of claims 1-4, wherein: the antibody or antigen-binding fragment thereof further comprises a heavy chain constant region and a light chain constant region,
the heavy chain constant region is a heavy chain constant region of IgG1 or a heavy chain constant region of IgG 4;
the light chain constant region is a Kappa light chain constant region.
6. The relevant biological material of the antibody or antigen binding fragment thereof according to any one of claims 1-5, characterized in that: the related biological material is any one of the following:
b1 A nucleic acid molecule encoding the antibody or antigen-binding fragment thereof of any one of claims 1-5;
b2 A nucleic acid molecule encoding the heavy and light chains of the antibody or antigen-binding fragment thereof of any one of claims 1-5;
b3 A nucleic acid molecule encoding the heavy chain variable region and the light chain variable region of the antibody or antigen binding fragment thereof of any one of claims 1-5;
B4 An expression cassette comprising any one of the nucleic acid molecules B1) to B3);
b5 A recombinant vector comprising any one of the nucleic acid molecules B1) to B3), or a recombinant vector comprising the expression cassette of B4);
b6 A recombinant microorganism comprising a nucleic acid molecule according to any one of B1) to B3), a recombinant microorganism comprising an expression cassette according to B4), or a recombinant microorganism comprising a recombinant vector according to B5).
7. Use of an antibody or antigen-binding fragment thereof according to any one of claims 1-5 or a biomaterial according to claim 6 for the preparation of a product for binding to a PV-1 protein.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310427097.3A CN116239694B (en) | 2022-05-09 | 2022-05-09 | Antibodies or antigen binding fragments thereof that specifically bind to PV-1 protein and uses thereof |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210501892.8A CN114920842B (en) | 2022-05-09 | 2022-05-09 | Antibodies or antigen binding fragments thereof that specifically bind to PV-1 protein and uses thereof |
CN202310427097.3A CN116239694B (en) | 2022-05-09 | 2022-05-09 | Antibodies or antigen binding fragments thereof that specifically bind to PV-1 protein and uses thereof |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210501892.8A Division CN114920842B (en) | 2022-05-09 | 2022-05-09 | Antibodies or antigen binding fragments thereof that specifically bind to PV-1 protein and uses thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
CN116239694A CN116239694A (en) | 2023-06-09 |
CN116239694B true CN116239694B (en) | 2023-12-15 |
Family
ID=82809213
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202310427094.XA Active CN116514979B (en) | 2022-05-09 | 2022-05-09 | Antibodies or antigen binding fragments HLPV-P09 thereof that specifically bind to PV-1 protein and uses thereof |
CN202210501892.8A Active CN114920842B (en) | 2022-05-09 | 2022-05-09 | Antibodies or antigen binding fragments thereof that specifically bind to PV-1 protein and uses thereof |
CN202310427100.1A Active CN116239695B (en) | 2022-05-09 | 2022-05-09 | Antibodies or antigen binding fragments thereof HLPV-P11 that specifically bind to PV-1 protein and uses thereof |
CN202310427097.3A Active CN116239694B (en) | 2022-05-09 | 2022-05-09 | Antibodies or antigen binding fragments thereof that specifically bind to PV-1 protein and uses thereof |
Family Applications Before (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202310427094.XA Active CN116514979B (en) | 2022-05-09 | 2022-05-09 | Antibodies or antigen binding fragments HLPV-P09 thereof that specifically bind to PV-1 protein and uses thereof |
CN202210501892.8A Active CN114920842B (en) | 2022-05-09 | 2022-05-09 | Antibodies or antigen binding fragments thereof that specifically bind to PV-1 protein and uses thereof |
CN202310427100.1A Active CN116239695B (en) | 2022-05-09 | 2022-05-09 | Antibodies or antigen binding fragments thereof HLPV-P11 that specifically bind to PV-1 protein and uses thereof |
Country Status (1)
Country | Link |
---|---|
CN (4) | CN116514979B (en) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108289951A (en) * | 2015-10-30 | 2018-07-17 | 豪夫迈·罗氏有限公司 | Anti- factor D antibody and conjugate |
CN108997497A (en) * | 2018-03-30 | 2018-12-14 | 苏州思坦维生物技术股份有限公司 | The monoclonal antibody and the preparation method and application thereof of specific bond hostage's film film bubble related protein PV-1 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100092470A1 (en) * | 2008-09-22 | 2010-04-15 | Icb International, Inc. | Antibodies, analogs and uses thereof |
CN102153647B (en) * | 2011-01-27 | 2012-07-04 | 中国人民解放军军事医学科学院生物工程研究所 | Anti-EGFR (epidemic growth factor receptor) humanized antibody L3-H3 and coding gene and application thereof |
US9493552B2 (en) * | 2013-11-15 | 2016-11-15 | China Synthetic Rubber Corporation | Therapeutic biologic for treatment of hepatocellular carcinoma |
AU2016344146A1 (en) * | 2015-10-30 | 2018-05-10 | Genentech, Inc. | Methods of measuring Factor D activity and potency of Factor D inhibitors |
CN105924524A (en) * | 2016-04-23 | 2016-09-07 | 同济大学苏州研究院 | Anti-c-Met chimeric antibody and application thereof |
JP2022550832A (en) * | 2019-09-30 | 2022-12-05 | 和▲ハク▼医▲薬▼(▲蘇▼州)有限公司 | Antibodies targeting CD3, bispecific antibodies and uses thereof |
-
2022
- 2022-05-09 CN CN202310427094.XA patent/CN116514979B/en active Active
- 2022-05-09 CN CN202210501892.8A patent/CN114920842B/en active Active
- 2022-05-09 CN CN202310427100.1A patent/CN116239695B/en active Active
- 2022-05-09 CN CN202310427097.3A patent/CN116239694B/en active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108289951A (en) * | 2015-10-30 | 2018-07-17 | 豪夫迈·罗氏有限公司 | Anti- factor D antibody and conjugate |
CN108997497A (en) * | 2018-03-30 | 2018-12-14 | 苏州思坦维生物技术股份有限公司 | The monoclonal antibody and the preparation method and application thereof of specific bond hostage's film film bubble related protein PV-1 |
Non-Patent Citations (2)
Title |
---|
"PV-1 is recognized by the PAL-E antibody and forms complexes with NRP-1";Johannes Keuschnigg 等;《Blood》;第120卷(第1期);第232-235页 * |
Dion,M.等."Chain B, Fab20D12 heavy chain".《genbank》.2021,ACCESSION 6VMJ_B. * |
Also Published As
Publication number | Publication date |
---|---|
CN116514979B (en) | 2024-05-07 |
CN116239695A (en) | 2023-06-09 |
CN114920842B (en) | 2023-07-04 |
CN116239695B (en) | 2024-03-22 |
CN116239694A (en) | 2023-06-09 |
CN114920842A (en) | 2022-08-19 |
CN116514979A (en) | 2023-08-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN112135626B (en) | anti-TIGIT antibodies and uses thereof | |
TWI796328B (en) | B7-h3 antibody, antigen-binding fragment thereof and medical application thereof | |
CN103987731B (en) | AGR2 blocking antibodies and application thereof | |
CN111647082B (en) | Antibodies against human IL-4RA and uses thereof | |
TW201315741A (en) | Human antigen binding proteins that bind to a complex comprising β -Klotho and an FGF receptor | |
JP2010162028A (en) | Human anti-ngf-neutralizing antibody as selective ngf pathway inhibitor | |
MXPA03000201A (en) | Antibodies to human mcp-1. | |
WO2016173558A1 (en) | Preparation and use of anti-norovirus gii.4 type murine monoclonal antibody | |
US9382316B2 (en) | Humanized anti-EMAP II antibody and use thereof | |
CN110028584B (en) | Bispecific antibodies against EGFR and MET proteins | |
US8344109B2 (en) | Anti-ricin antibody | |
CN116239694B (en) | Antibodies or antigen binding fragments thereof that specifically bind to PV-1 protein and uses thereof | |
CN109879966B (en) | Humanized design and expression verification based on murine CD19 antibody | |
CN116731169A (en) | Nano antibody with sortilin 1 specificity and application thereof | |
CN113840836A (en) | Anti-connective tissue growth factor antibody and application thereof | |
CN113912712B (en) | Preparation and application of monoclonal antibody for resisting alpha-synuclein | |
CN114127110B (en) | anti-CGRP antibodies and uses thereof | |
CA3152860A1 (en) | Anti-tfpi monoclonal antibodies | |
MX2011004244A (en) | Ligands that have binding specificity for dc-sign. | |
CN114957471B (en) | Humanized antibody specifically binding to human plasma membrane vesicle associated protein PV-1 and application thereof | |
CN109593134A (en) | The Humanized monoclonal antibodies and its preparation of anti-CD20 | |
CN115947855B (en) | Preparation of anti-CD 24 antibodies and uses thereof | |
CN115850499A (en) | Antigen binding molecule specifically binding to ANGPTL3 and PCSK9 and medical application thereof | |
CN117915950A (en) | Multispecific antibody and application thereof | |
TW202325743A (en) | Antigen-binding molecule that specifically binds to cd38, bcma and cd3 and medical uses thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
TA01 | Transfer of patent application right | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20231116 Address after: 9/F, Building B, Innovation Incubation Base, South Zhongyuan Technopole, East Sanquan Road, Longhu Middle Ring West Road, Zhengzhou Area, Zhengzhou Pilot Free Trade Zone, 450000 Henan Province Applicant after: Hualan Gene Engineering (Henan) Co.,Ltd. Address before: 453000 No.1-1 Huanghe Road, Pingyuan demonstration area, Xinxiang City, Henan Province Applicant before: HUALAN GENETIC ENGINEERING Co.,Ltd. |
|
GR01 | Patent grant | ||
GR01 | Patent grant |